OTHER INFORMATION
−Removed: See Note 8 to the Financial Statements for discussion of our prior period financial restatements.
+Added: On October 11, 2022, the board of directors of the Company approved and adopted the Amended and Restated Bylaws of the Company, which became effective the same day, in order to, among other things (i) update the name of the Company from “Nuclear Medical Systems, Inc.” to “Biomerica, Inc.”, (ii) change the annual meeting date from October 15 to any such date that the Board shall fix each year, (iii) change the voting standard for all matters other than election of directors from a plurality vote to a majority vote, (iv) update the requirements for the list of stockholders, (v) revise the indemnification provisions, and (vi) add new forum selection provisions.
+Added: The preceding summary of the Amended and Restated Bylaws is qualified in its entirety by reference to, and should be read in connection with, the complete copy of the Amended and Restated Bylaws filed herewith as Exhibit 3.1.
The following exhibits are filed or furnished as part of this quarterly report on Form 10-Q:
+Added: Amended and Restated Bylaws of the Company
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act — Zackary S.
9 unchanged sentences
101.PRE-XBRL Taxonomy Extension Presentation Linkbase Document
+Added: 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibits 101)
+Added: * Filed herein.
** Filed herewith.
1 unchanged sentence
BIOMERICA, INC.
−Removed: April 14, 2022
+Added: October 13, 2022
/S/ Zackary S.
1 unchanged sentence
(Principal Executive Officer)
−Removed: April 14, 2022
+Added: October 13, 2022
/S/ Steve Sloan
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.